Ligand Pharma (LGND) Tops Q2 EPS by 24c, Revenues Beat; Raises FY20 EPS/Revenue Guidance Above Consensus
Go back to Ligand Pharma (LGND) Tops Q2 EPS by 24c, Revenues Beat; Raises FY20 EPS/Revenue Guidance Above Consensus| LIGAND PHARMA (NASDAQ: LGND) | Delayed: 283.49 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $283.49 | 52 Week High | $139.79 | |||
| Open | $283.49 | 52 Week Low | $82.07 | |||
| Day High | $283.49 | P/E | 659.28 | |||
| Day Low | $283.49 | EPS | $0.43 | |||
| Volume | 733 | |||||

